With AstraZeneca's vaccine trials resuming worldwide, results have shown good immune responses in young and older adults alike. However, trials are yet to resume in the United States as volunteers await their second dose.
Novavax's vaccine candidate has produced the highest number of antibodies according to vaccine experts. As they enter the final stage of human trials, they will also be testing some participants with the flu vaccine at the same time.
Johnson & Johnson will be entering phase three of human trials, including 60,000 participants from three continents. They also continue to look for other possible treatments for coronavirus as their vaccine candidate completes safety and efficacy trials.
The Gamaleya vaccine is the first the receive regulatory approval in the world after two months of testing. Scientists around the world are skeptic, including the Association of Clinical Trials Organizations, of its efficacy and safety.